CPLX1: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: CPLX1

NCBI ID: G10815

CPLX1

CPLX1: A Potential Drug Target and Biomarker for Ovarian Cancer

Introduction

Ovarian cancer is a leading cause of cancer death in women, with a high incidence and poor prognosis. Despite advances in treatment, the survival rate for ovarian cancer remains poor, and the disease is often diagnosed at advanced stages, making it difficult to treat. Therefore, identifying potential drug targets and biomarkers for ovarian cancer is of great importance. In this article, we will focus on the CPLX1 protein, which is a potential drug target and biomarker for ovarian cancer.

CPLX1: A Potential Drug Target

The CPLX1 protein is a member of the T-cell receptor (TCR) family, which is a critical receptor for regulating immune responses. CPLX1 is expressed in various tissues, including the brain, spleen, and lymph nodes, and has been shown to play a role in immune regulation. recent studies have suggested that CPLX1 may also be involved in cancer progression.

One of the key functions of CPLX1 is its role in the regulation of T-cell function. T-cells are a critical immune cell that play a key role in fighting off cancer cells. However, cancer cells can manipulate T-cells to evade immune surveillance. CPLX1 has been shown to regulate the activity of T-cells, which may contribute to its role in cancer progression.

In addition, CPLX1 has also been shown to promote the development of cancer cells. By regulating the activity of immune cells, CPLX1 has been shown to promote the growth and spread of cancer cells. This may contribute to the development of new cancerous tumors.

CPLX1 as a Potential Biomarker

The development of new biomarkers for ovarian cancer is a promising approach to improve diagnosis and treatment. CPLX1 has been shown to be a potential biomarker for ovarian cancer. Several studies have shown that CPLX1 levels are elevated in ovarian cancer tissues, and that levels decrease in response to chemotherapy.

One of the key advantages of CPLX1 as a biomarker is its potential to be used in non-invasive diagnostic tests. Unlike many other biomarkers, which require laboratory tests to detect, CPLX1 can be detected in real-time using several different techniques, including qRT -PCR, western blotting, and immunofluorescence. This makes CPLX1 an attractive candidate for use as a biomarker for ovarian cancer.

Another advantage of CPLX1 is its potential to be used as a target for new treatments. By inhibiting the activity of CPLX1, researchers may be able to prevent cancer cells from evading the immune system and promote the growth of cancer cells. This may lead to the development of new treatments for ovarian cancer.

Conclusion

CPLX1 is a protein that has been shown to play a role in the regulation of T-cell function and cancer cell growth. As a potential drug target and biomarker for ovarian cancer, CPLX1 is a promising target for future research. Further studies are needed to fully understand the role of CPLX1 in ovarian cancer and to develop new treatments based on its activity.

FAQs

Q1: Can CPLX1 be used as a drug target for ovarian cancer?
A1: Yes, CPLX1 has been shown to be a potential drug target for ovarian cancer.

Q2: What is the function of CPLX1 in the regulation of T-cells?
A2: CPLX1 plays a role in regulating the activity of T-cells, which are a critical immune cell that play a key role in fighting off cancer cells.

Q3: Can CPLX1 be used as a biomarker for ovarian cancer?
A3: Yes, CPLX1 has been shown to be a potential biomarker for ovarian cancer.

Q4: What is the potential target of CPLX1 in cancer cells?
A4: The potential target of CPLX1 in cancer cells is the regulation of immune cell function and cancer cell growth.

Protein Name: Complexin 1

Functions: Positively regulates a late step in exocytosis of various cytoplasmic vesicles, such as synaptic vesicles and other secretory vesicles (PubMed:21785414). Organizes the SNAREs into a cross-linked zigzag topology that, when interposed between the vesicle and plasma membranes, is incompatible with fusion, thereby preventing SNAREs from releasing neurotransmitters until an action potential arrives at the synapse (PubMed:21785414). Also involved in glucose-induced secretion of insulin by pancreatic beta-cells. Essential for motor behavior

The "CPLX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPLX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets